Clinical Roundup Zejula shows durable, sustained long-term PFS benefit in first-line platinum-responsive advanced ovarian cancer September 16, 2022Vol.48 No.33
Clinical Roundup Study shows specific sequence of drugs reduces cost of treating metastatic breast cancer while preserving quality of life September 16, 2022Vol.48 No.33
Clinical Roundup Strata Oncology expands Strata PATH trial to eight Sarah Cannon Research Institute sites September 16, 2022Vol.48 No.33
Clinical Roundup The WiTT Group and Mary Crowley Cancer Research form partership to enhance access to clinical trials September 16, 2022Vol.48 No.33
Clinical Roundup Pralsetinib achieves tissue-agnostic benefits for patients with RET gene fusions September 16, 2022Vol.48 No.33
Clinical Roundup Phase III study of Cytalux injection for intraoperative imaging of ovarian cancer shows identification of additional lesions September 16, 2022Vol.48 No.33
Drugs & Targets FDA issues safety alert for squamous cell carcinoma and various lymphomas in scar tissue around breast implants September 16, 2022Vol.48 No.33
Drugs & Targets Roche’s VENTANA PD-L1 (SP263) Assay receives CE IVD approval to identify patients with locally advanced and metastatic NSCLC eligible for Libtayo September 16, 2022Vol.48 No.33
Drugs & Targets MD Anderson and Virogin Biotech form collaboration to accelerate oncolytic virus R&D September 16, 2022Vol.48 No.33
Drugs & Targets OU Health Stephenson Cancer Center joins Caris’ Precision Oncology Alliance September 16, 2022Vol.48 No.33
